Weei-Chin Lin, M.D., Ph.D.
Dan L. Duncan Endowed Professor
Positions
- Dan L. Duncan Endowed Professor
-
Medicine-Hematology & Oncology
ºÚÁÏÉçÇø
Houston, TX, US
- Professor
-
Department of Molecular and Cellular Biology
ºÚÁÏÉçÇø
Houston, Texas, United States
- Dan L Duncan Endowed Professor
-
Dan L Duncan Comprehensive Cancer Center
ºÚÁÏÉçÇø
Houston, Texas, United States
- Co-Director
-
Cancer & Cell Biology Graduate Program
ºÚÁÏÉçÇø
- Faculty
-
Development, Disease Models & Therapeutics Graduate Program
ºÚÁÏÉçÇø
Addresses
- Alkek Building for Biomedical Research (Office)
-
Room: ABBR-R410
Houston, TX, 77030
United States
Education
- PhD from Johns Hopkins University School Of Medicine
- 05/1993 - Baltimore, Maryland, United States
- MD from National Taiwan University
- 06/1986 - Taipei, Taiwan, Taiwan
- Post-Doctoral Fellowship at Johns Hopkins University School of Medicine
- 06/1994 - Baltimore, Maryland, United States
- Residency at Duke University Medical Center
- 06/1996 - Durham, North Carolina, United States
- Clinical Fellowship at Duke University Medical Center
- 06/1999 - Durham, North Carolina, United States
Certifications
- Texas Medical Board
- Diplomate, American Board of Internal Medicine
- Subspecialty in Medical Oncology, ABIM
- Subspecialty in Hematology, ABIM
Honors & Awards
- Dan Duncan Professorship of Oncology
- ºÚÁÏÉçÇø (01/2010)
- The Leukemia & Lymphoma Society Scholar
- (07/2006 - 06/2011)
- General Motors Cancer Research Scholar
- (01/2002 - 01/2005)
- Howard Hughes Medical Institute Junior Faculty Development Award
- (06/2001 - 06/2004)
- Damon Runyon-Walter Winchell Physician Scientist Award
- Duke University (04/1999 - 05/2001)
- The Martin and Carol Macht Research Prize
- Johns Hopkins University (05/1993)
Professional Interests
- Cell cycle regulation
- Development of cancer therapeutics
- Clinical hematology
Professional Statement
I am a physician scientist with solid training in both clinical medicine and basic research. My lab is working on fundamental cell cycle/cell death regulation, and protein modifications, particularly focused on the pRb/E2F and p53 pathways in the oncogenic activation. We have identified several important pathways that are deregulated in cancer. My goal is to develop novel cancer therapy based on our own original discoveries.
Selected Publications
-
" ;
-
Fang-Tsyr Lin, Shwu-Jiuan Lin, Kang Liu , Yang Xiao, Lidija A Wilhelms Garan, Helena Folly-Kossi, Weei-Chin Lin. " " Sci Adv.. 2026 Aug 7; 7 (12(32)) : eaeg1996.
Pubmed PMID: . -
Kang Liu, Lidija AW Garan, Fang-Tsyr Lin, Weei-Chin Lin. " " Communications Biology. 2025 ; 8(1) (1522)
Pubmed PMID: . -
Fang-Tsyr Lin, Kang Liu, Lidija A Wilhelms Garan, Helena Folly-Kossi, Yongcheng Song, Shwu-Jiuan Lin, Weei-Chin Lin. " " Proc Natl Acad Sci U S A. 2023 Oct 25;
Pubmed PMID: .
Intellectual Property
- Method Patent #US 9,636,323 (Approved)
- Covers methods of treating TopBP1-overexpressing cancers using small-molecule inhibitors targeting the TopBP1 BRCT7/8 domain.
- Co Inventors: Weei-Chin Lin, Pinki Chowdhury, Gregory E. Lin, Kang Liu, Yongcheng Song, Fang-Tsyr Lin
- Product Patent #PCT/US24/48843 (Pending)
- Small molecule inhibitors of TopBP1-BRCT7/8 and uses thereof
- Co Inventors: Weei-Chin Lin, Fang-Tsyr Lin
to edit your profile